疫苗诱导免疫性血栓性血小板减少症:已知与未知
新冠疫苗接种全球推进中出现罕见的疫苗相关结局,特征为血小板减少和血栓形成,伴血小板活化抗血小板因子4抗体。本文总结当前对疫苗诱导免疫性血栓性血小板减少症(VITT)的认识。
要点
- VITT表现为血小板减少和血栓形成,伴血小板活化抗PF4抗体。
- VITT与特定COVID-19疫苗相关,信息仍在快速演变。
- 需认识VITT以早期识别和处理。
核心结论
- VITT是某些COVID-19疫苗接种后出现的罕见并发症,特征为血小板减少、血栓形成和抗PF4抗体。
主要发现
- VITT表现为血小板减少和血栓形成,与血小板活化抗血小板因子4抗体相关。
局限性
- 对VITT临床情况的认识仍在快速演变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of vaccines to fight COVID-19 has been a remarkable medical achievement. However, this global immunization effort has been complicated by a rare vaccine-related outcome characterized by thrombocytopenia and thrombosis in association with platelet-activating anti-platelet factor 4 antibodies. In this Spotlight, we will discuss the recently described complication of vaccine-induced immune thrombotic thrombocytopenia (VITT) occurring in response to certain COVID-19 vaccines. Although information about this clinical condition is rapidly evolving, we will summarize our current understanding of VITT.
引用
- Arepally GM, Ortel TL. Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. Blood. 2021. PMID: 34323940. doi:10.1182/blood.2021012152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。